Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, December 7, 2011

Pradaxa Benefit Outweighs Bleeding Risk, FDA Says

New news on the Pradaxa front. Quiz your doctors on this.
http://www.medpagetoday.com/Cardiology/Arrhythmias/30075?utm_source=breaking-news&utm_medium=email&utm_campaign=breaking-news

The FDA has announced today that patients taking the anticoagulant dabigatran (Pradaxa) to reduce the risk of stroke associated with atrial fibrillation should continue to take the drug as directed, despite post-market reports of severe bleeding.

A report of about 50 cases of fatal bleeding worldwide associated with the drug surfaced in November.

Drugmaker Boehringer Ingelheim said at the time that dabigatran's safety profile was in line with that seen during the RE-LY clinical trial, which compared dabigatran with warfarin in more than 18,000 participants.

And the FDA noted in Wednesday's announcement that dabigatran's label contains a warning about significant and sometimes fatal bleeds, and noted that in the randomized RE-LY trial, both arms had similar major bleeding rates.

Although the agency is continuing to monitor the situation, at this time it "believes that Pradaxa provides an important health benefit when used as directed and recommends that healthcare professionals who prescribe Pradaxa follow the recommendations in the approved drug label."

In its statement the agency said that patients should not stop taking the drug without consulting a physician because doing so could increase the risk of stroke.

In the meantime, physicians and healthcare professionals should report any adverse events or side effects associated with dabigatran to FDA's MedWatch Safety Information and Adverse Event Reporting Program.

No comments:

Post a Comment